Integrating Liver-Chip data into pharmaceutical decision-making processes
Author:
Affiliation:
1. Chief Technology Officer, Emulate Inc, Boston, MA, USA
2. Chief Scientific Officer, Emulate Inc, Boston, MA, USA
Publisher
Informa UK Limited
Subject
Drug Discovery
Link
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2023.2255127
Reference35 articles.
1. Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Guidance for industry drug-induced Liver injury: premarketing clinical evaluation. Drug-induced Liver injury: premarketing clinical evaluation (2009). Available from: https://www.fda.gov/media/116737/download
2. WITHDRAWN—a resource for withdrawn and discontinued drugs
3. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
4. Drug-induced Liver injury;David S;US Gastroenterol Hepatol Rev,2010
5. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver;2024-01-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3